Voyager Therapeutics, Inc. (VYGR)

From the record

Voyager Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Voyager Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $14 million in fiscal 2016 to $40 million in fiscal 2025, up 12.3% a year; it rose in 4 of 9 years; the deepest fall was 84% from fiscal 2023 to fiscal 2025; net income was positive in 2 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Voyager Therapeutics, Inc. lost about 61 cents for every dollar of shareholders' money. Leverage: it owed about 22 cents per dollar of assets, and net share issuance: its share count grew 1.8% over the year (the filed statements).

From the record

Voyager Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $40 million in fiscal 2025 ranks in the top 45% by size; a net margin of -296.5% ranks in the bottom 49%; revenue growth of -0.4% a year over the last 3 filed years ranks in the bottom 40% (its annual reports).

From the record

Voyager Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Sandrock, Alfred (President and CEO, as filed), filing under that title since 2022-03-23, 4.6 years (bottom 46% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 4.2 years (bottom 23%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 36%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Voyager Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $65 million against no long-term debt tagged leaves 25.9% of its assets as net cash, bottom 49% of its family; cash from operations less capital spending is -334.5% of revenue (bottom 42%); research spending of 333.6% of revenue (top 37%) (its annual report).

From the record

Voyager Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.4% a year over the last three filed years against 12.3% over all 10, slowing (bottom 40% of its family); the newest year grew -49.6% (bottom 11%); research spending grew 30.4% a year (top 9%); capital spending grew 1.4% a year (top 26%) (its annual reports). Voyager Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Voyager Therapeutics, Inc.'s newest year against its own record: revenue of $40 million in fiscal 2025 came in 63.9% below the $112 million its prior three years' pace pointed to (bottom 11% of its family); net income of $120 million against a prior three-year average of $7 million (bottom 2%); a net margin of a loss larger than its revenue against -47.3% before (bottom 19%) (its annual reports).